Search
Tixagevimab
go.drugbank.com/drugs/DB16394ApprovedInvestigationalTixagevimab, in combination with [cilgavimab], was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for … [L39411] EVUSHELD was granted marketing authorization by the EMA on March 28, 2022,[L41454] and was approved in Canada soon after, on April 14, 2022.
Alclofenac
go.drugbank.com/drugs/DB13167ApprovedWithdrawnIt was withdrawn from the market in the United Kingdom in 1979.
Polycarbophil
go.drugbank.com/drugs/DB09311ApprovedWithdrawnIt is insoluble in water, dilute acids, and dilute alkali.
Categories: Compounds used in a research, industrial, or household settingPiflufolastat F 18
go.drugbank.com/drugs/DB14805ApprovedInvestigationalProstate cancer is the most common non-cutaneous malignancy affecting men in North America[A235344] - despite this, an ongoing challenge in prostate cancer therapy is the difficulty in imaging the extent … levels roughly 1000-fold greater than elsewhere in the body, and even higher in prostate cancer tissue.
Sodium zirconium cyclosilicate
go.drugbank.com/drugs/DB14048ApprovedInvestigationalSodium zirconium cyclosilicate is approved as the trade product Lokelma developed by AstraZeneca - an insoluble, non-absorbed sodium zirconium silicate, formulated as a powder for oral suspension that … from three double-blind, placebo-controlled trials and two open-label trials which showed that the onset of action was approximately 1.0 hour and the median time to achieving normal potassium levels in
Categories: Compounds used in a research, industrial, or household settingSelumetinib
go.drugbank.com/drugs/DB11689ApprovedInvestigational[A193608] Use of selumetinib in this population has shown efficacy in shrinking associated tumours and is linked to other positive clinical outcomes. … [A193533] Following its initial FDA approval on April 10, 2020,[L49991] and Health Canada approval on August 23, 2022,[L49986] the regulatory landscape has evolved.
Sebetralstat
go.drugbank.com/drugs/DB18305ApprovedInvestigationalFood and Drug Administration approved sebetralstat on July 7, 2025, for treating acute HAE attacks in patients aged 12 years and older [L53533, L53538]. … This plasma kallikrein inhibitor works by reducing bradykinin, the substance that causes the characteristic swelling in HAE attacks [L53533]. The U.S.
Categories: Drugs Used in Hereditary AngioedemaSynonyms: 1H-Pyrazole-4-carboxamide, N-[(3-fluoro-4-methoxy-2-pyridinyl)methyl]-3-methoxymethyl)-1-[[4-[(2-oxo-1(2H)-pyridinyl)methyl]phenyl]methyl]-, N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1(2H)-yl)methyl]phenyl}methyl)-1H-pyrazol-4-carboxamideChlordiazepoxide
go.drugbank.com/drugs/DB00475ApprovedIllicitAn anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal.
Dioxybenzone
go.drugbank.com/drugs/DB11221ApprovedWithdrawnDioxybenzone is an approved sunscreen ingredient in concentrations up to 3% [L2525]. … Dioxybenzone, or benzophenone-8, is an organic compound derived from [DB01878] that is used as a sunscreen agent. It absorbed UV-B and UV-AII rays.
Abaloparatide
go.drugbank.com/drugs/DB05084ApprovedInvestigationalAbaloparatide is an N-terminal analog of parathyroid hormone-related protein (PTHrP) [A256778] and an agonist at the parathyroid hormone type 1 (PTH1) receptor. … [L740] It was first approved by the FDA on April 28, 2017,[A256748] for the treatment of osteoporosis in postmenopausal women and is also used to increase bone density in men with osteoporosis.